PTGX stock: buy or sell?
September 20th, 2019
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based chemical entities to address various unmet medical needs.
Should I buy PTGX stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Protagonist Therapeutics stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Protagonist Therapeutics stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 2 ratings published for PTGX stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-2-22||BMO Capital Markets||n/a||Outperform|
PTGX stock analysis
Shares of Protagonist Therapeutics ended today at $13.81 and stayed constant a slightly fine 0.22%.
Shares of Protagonist Therapeutics closed today at $13.81 and stayed steady a slightly fine 0.22%. On Aug/13 PTGX price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock.
Protagonist Therapeutics plummed a spooky -6.82% this week. Early September PTGX climbed an amazing 16.26% in just one week.
Since mid August when PTGX stock price broke up the SMA40w line, it gained $4.39 (46.60%). Since SMA20d and SMA40w crossed up early April, PTGX price climbed $0.85 per share (6.56%).
PTGX stock price history
PTGX IPO was on August 11th, 2016 at $12.00 per share1. Since then, PTGX stock surged a 15.10%, with a yearly average of 5.00%. If you had invested right after PTGX's IPO a $1,000 in PTGX stock in 2016, it would worth $151.00 today.
1: Adjusted price after possible price splits or reverse-splits.
PTGX stock historical price chart
PTGX stock reached 52-week highs on Sep/10 at $16.67, and all-time highs 2016-12-06 with a price of 26.36.
PTGX stock price target is $20.00Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we found 2 price predictions for Protagonist Therapeutics stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-2-22||BMO Capital Markets||Initiates||n/a||$17.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, Protagonist reported its latest financial data, posting an amazing climb for the Earnings per Share (EPS) ratio. Experts expected $-0.42 per share, but Protagonist posted $-0.57.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Protagonist Therapeutics annual turnover climbed an exceptional 54.14% to $30.93 million dollars from $20.06 marked in 2017. Aligned with this, its income margin (compared to sales) boosted to -125.87%, that is $-38.92 million.
|2017||$20 M||-||$-36.96 M-184.2%||-|
|2018||$31 M||54.14%||$-38.92 M-125.9%||5.32%|
Quarterly financial resultsProtagonist Therapeutics posted $2.35 M in sales for 2018-Q4, a -61.53% decline compared to previous quarter. Reported quarter earnings marked $-13.87 M with a profit margin of -589.25%. Profit margin plummed a -446.45% compared to previous quarter when profit margin was -142.80%. When comparing sales to same quarter last year, Protagonist sales marked a spooky correction and collapsed a -79.14%. Looking back to recent quarterly results, Protagonist posted 2 negative quarters in a row.
|2017-Q3||$9 M||-||$-4.83 M-54.9%||-|
|2017-Q4||$11 M||28.48%||$-3.05 M-27.1%||-36.75%|
|2018-Q1||$11 M||-4.44%||$-7.66 M-71.1%||151.02%|
|2018-Q2||$12 M||8.28%||$-8.66 M-74.2%||13.08%|
|2018-Q3||$6 M||-47.60%||$-8.74 M-142.8%||0.83%|
|2018-Q4||$2 M||-61.53%||$-13.87 M-589.2%||58.73%|
Protagonist ownershipWhen you are planning to invest in a company, it's worth to have a look its ownership structure.
Protagonist shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 5.26% of all shares.
Bearish positions for PTGX stock account 0.00%, no big difference from last month.
For a better context understanding, the next table shows ownership data compared to other related stocks:
|Market cap||$323.2 M||$259.4 M||$260.8 M|
|Total shares||23.4 M||120.7 M||49.4 M|
|Float shares||16.3 M||102.9 M||45.3 M|
|- Institutional holdings (%)||90.4%||95.2%||72.8%|
|- Insider holdings (%)||5.3%||2.5%||0.2%|
|Shares in short selling||0.0%||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$13.70 - $13.92|
|Average true range||$0.99|
|50d mov avg||$12.41|
|100d mov avg||$11.85|
|200d mov avg||$10.40|
Protagonist performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. In the following table, we compare Protagonist Therapeutics performance to PDL BioPharma and Pieris Pharmaceuticals: